III

Latest Posts

First and solely BTK inhibitor to display favorable general survival pattern vs. standard-of-care chemoimmunotherapy...

Market

CALQUENCE ® (acalabrutinib) plus chemoimmunotherapy decreased the chance of illness development or dying by 27% vs. customary of care in sufferers with untreated mantle...

‹‹‹First and solely EGFR inhibitor and focused remedy to point out profit in Stage...

Market

TAGRISSO ® (osimertinib) decreased the danger of illness development or demise by 84% in sufferers with unresectable, Stage III EGFR-mutated lung most cancers vs....